AMR April-May 2026 Breakthrough Wave: AI-Designed Antimicrobial Peptides + Phage Therapy + Repurposed Drugs
April-May 2026 produced an unusual concentration of peer-reviewed advances against antimicrobial resistance, with peptide therapeutics anchoring much of the progress. The Frontiers in Bioinformatics March 17 review documented an AI/LLM pipeline (ProteoGPT) that produced 17 active peptides out of 18 designed (94.4% hit rate) in 48 days — collapsing the traditional discovery timeline. A Nature Microbiology generative-AI approach produced novel AMPs against multidrug-resistant bacteria with anti-inflammatory effects and minimal cytotoxic risk. Other April-May 2026 breakthroughs: Houston Methodist's CAMPER engineered against MRSA, the Manchester team's alternative ligase pathway to penicillins, and the Indian Institute of Technology Roorkee antibacterial peptide-drug conjugate against NDM-1/IMP-1 metallo-beta-lactamase pathogens. The combined wave signals the peptide-design stack has matured enough to compete directly with small-molecule antibiotic development.